• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Around the World

Remdesivir has received FDA’s emergency approval to treat COVID-19, according to Trump

Emmanuel Abara BensonbyEmmanuel Abara Benson
3 years ago
in Around the World, Coronavirus
Remdesivir, new covid-19 strain
Share on FacebookShare on TwitterShare on Linkedin

President Donald Trump said the remdesivir drug has been given emergency use authorisation by the FDA to treat Coronavirus patients in the United States of America. Trump made the announcement yesterday during a televised address that was covered by CNBC. 

What we know: The remdesivir drug is manufactured by American pharmaceutical company, Gilead Sciences. Data from the Coronavirus trial testing of the drug showed that patients who took it recovered within eleven days. This indicates a shortened recovery period, compared to other drugs that have been used to treat the virus. 

More on the drug: Gilead Sciences’ Chief Executive Officer, Daniel O’Day, who was present during Trump’s live announcement, used the occasion “to thank the collaborators that brought remdesivir to this point and many of our people that have been part of this, in fact, the caregivers”.

He also stated that the company will be donating 1.5 million vials of the intravenous drug. 

In the meantime, the company’s stock initially reacted negatively to this development, having declined by 4.8% to $79.95 as at close of market trading on the New York Stock Exchange, Friday. 

However, the stock reportedly went up by almost 2% during extended trading hours. Gilead Sciences’ valuation is a whopping $101 billion. 

What you should know: The emergency use authorisation for remdesivir does not mean that the drug has been given express approval by America’s Food and Drug Administration, FDA. As a matter of fact, the drug has not undergone any thorough review that would then give it the appropriate approval to treat patients. However, doctors can use it to treat patients for now due to the emergency nature of the Coronavirus pandemic. 

Researchers have, however, pointed out that remdesivir’s side effects could be as mild as nausea and vomiting, or as severe as liver damage. 

Recall that this is not the first time President Trump has been too eager to present a drug as a cure for the deadly virus. Recall that in March, Trump announced that the FDA approved the malaria drug – Chloroquine – as a cure for COVID-19. The FDA later faulted this claim.  

Tags: FDAGilead Sciencesremdesivir drug

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

hfm
UBA
Mega Millions
Mega Millions
fidelity banner
HFM







NM newsletters

Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

Recent News

  • Senate approves 20 Special advisers for Tinubu
  • Live your dream in the TECNO PHANTOM V Fold world of endless possibilities
  • Flutterwave collaborates with Token.io to ease bank transfer to UK, EU

Follow us on social media:

Recent News

Senate approves 20 Special advisers for Tinubu

Senate approves 20 Special advisers for Tinubu

June 6, 2023
PHANTOM V FOLD

Live your dream in the TECNO PHANTOM V Fold world of endless possibilities

June 6, 2023
  • Download Nairametrics iOS App
  • Download Nairametrics Android App
  • Home
  • Exclusives
  • Markets
  • Industries
  • Economy
  • Business News
  • Financial Literacy
  • Opinions

© 2023 Nairametrics

No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
  • Login
  • Sign Up

© 2023 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In